Advertisement
Australia markets close in 55 minutes
  • ALL ORDS

    8,080.90
    -37.40 (-0.46%)
     
  • ASX 200

    7,808.90
    -39.20 (-0.50%)
     
  • AUD/USD

    0.6629
    +0.0007 (+0.11%)
     
  • OIL

    77.05
    -0.52 (-0.67%)
     
  • GOLD

    2,372.70
    -20.20 (-0.84%)
     
  • Bitcoin AUD

    104,758.94
    -409.54 (-0.39%)
     
  • CMC Crypto 200

    1,514.71
    -11.70 (-0.77%)
     
  • AUD/EUR

    0.6120
    +0.0010 (+0.17%)
     
  • AUD/NZD

    1.0831
    -0.0027 (-0.25%)
     
  • NZX 50

    11,773.75
    +41.47 (+0.35%)
     
  • NASDAQ

    18,705.20
    -8.59 (-0.05%)
     
  • FTSE

    8,370.33
    -46.12 (-0.55%)
     
  • Dow Jones

    39,671.04
    -201.95 (-0.51%)
     
  • DAX

    18,680.20
    -46.56 (-0.25%)
     
  • Hang Seng

    18,913.51
    -282.09 (-1.47%)
     
  • NIKKEI 225

    39,085.26
    +468.16 (+1.21%)
     

Was This Acquisition a Savvy Play by This Big Pharma Stock?

Was This Acquisition a Savvy Play by This Big Pharma Stock?

Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.